Pulmonary fibrosis: New horizons and clinical solutions: A review II Expert Council “Idiopathic pulmonary fibrosis and progressive pulmonary fibroses. Real Practice” Symposium Review October 26, 2024, Sochi, Russia
- Authors: Avdeev S.N.1, Chikina S.I.1, Trushenko N.V.1,2, Kiniaikin M.F.3,4
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Research Institute of Pulmonology
- Pacific State Medical University
- Primorsky Territory Clinical Hospital No.1
- Issue: Vol 27, No 3 (2025): Оториноларингология и пульмонология
- Pages: 165-178
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/309758
- DOI: https://doi.org/10.26442/20751753.2025.3.203266
- ID: 309758
Cite item
Full Text
Abstract
This review summarizes key materials from Symposium II of the Expert Council on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis, held on October 26, 2024, in Sochi. It highlights recent scientific advances in understanding the pathogenesis of IPF, including genetic factors and the role of fibrosenescence. Discussed are the updated clinical guidelines from the European Respiratory Society (ERS), American Thoracic Society (ATS), Japanese Respiratory Society (JRS), and Asociación Latinoamericana del Thorax (ALAT) (2022) on diagnosis, emphasizing the value of transbronchial lung cryobiopsy and high-resolution computed tomography (HRCT) patterns. Special attention is given to novel therapeutic approaches: antifibrotic drugs (nintedanib, pirfenidone), inhaled formulations, and promising agents in clinical trial phases. Research findings on the prognostic significance of symptoms (cough, crackles) and the efficacy of bioequivalent drugs are reviewed. Data from the Russian IPF patient registry underscore the importance of standardized diagnostics and monitoring. The material includes a clinical case analysis demonstrating long-term pirfenidone therapy. This review is intended for pulmonologists, rheumatologists, and specialists in interstitial lung diseases.
Full Text
##article.viewOnOriginalSite##About the authors
Sergey N. Avdeev
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: editor@omnidoctor.ru
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowSvetlana I. Chikina
Sechenov First Moscow State Medical University (Sechenov University)
Email: editor@omnidoctor.ru
Cand. Sci. (Med.)
Russian Federation, MoscowNatalia V. Trushenko
Sechenov First Moscow State Medical University (Sechenov University); Research Institute of Pulmonology
Email: editor@omnidoctor.ru
Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowMikhail F. Kiniaikin
Pacific State Medical University; Primorsky Territory Clinical Hospital No.1
Email: editor@omnidoctor.ru
Cand. Sci. (Med.)
Russian Federation, Vladivostok; VladivostokReferences
- Chaudhuri N, Spagnolo P, Valenzuela C, et al. Treatment patterns and patient journey in progressive pulmonary fibrosis. Respir Res. 2024;25(1):364. doi: 10.1186/s12931-024-02995-9
- Selman M, Pardo A. Idiopathic pulmonary fibrosis: From common microscopy to single-cell biology and precision medicine. Am J Respir Crit Care Med. 2024;209(9):1074-81. doi: 10.1164/rccm.202309-1573PP
- Adegunsoye A, Kropski JA, Behr J, et al. Genetics and genomics of pulmonary fibrosis: Charting the molecular landscape and shaping precision medicine. Am J Respir Crit Care Med. 2024;210(4):401-23. doi: 10.1164/rccm.202401-0238SO
- Chikina S, Cherniak A, Merzhoeva Z, et al. Russian Registry of idiopathic pulmonary fibrosis: Clinical features, treatment management, and outcomes. Life (Basel). 2023;13(2):435. doi: 10.3390/life13020435
- Liao YW, Chen YM, Liu MC, et al. Multidisciplinary-derived clinical score for accurate prediction of long-term mortality in fibrotic lung disease patients. Eur J Med Res. 2024;29(1):69. doi: 10.1186/s40001-024-01644-7
- Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44. doi: 10.1164/rccm.202311-2101OC
- Wu Z, Smith DJF, Yazbeck L, et al. Cough Severity Visual Analog Scale assesses cough burden and predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2024;209(9):1165-7. doi: 10.1164/rccm.202311-2169LE
- Fujita K, Kanemitsu Y, Ohkubo H, et al. Productive cough associated with patient-reported outcomes and computed tomography analysis results in idiopathic pulmonary fibrosis. ERJ Open Res. 2024;10(5):00527-2024. doi: 10.1183/23120541.00527-2024
- Sgalla G, Simonetti J, Di Bartolomeo A, et al. Reliability of crackles in fibrotic interstitial lung disease. Respir Res. 2024;25(1):352. doi: 10.1186/s12931-024-02979-9
- Hozumi H, Miyashita K, Nakatani E, et al. Antifibrotics and mortality in idiopathic pulmonary fibrosis: External validity and avoidance of immortal time bias. Respir Res. 2024;25(1):293. doi: 10.1186/s12931-024-02922-y
- Romero Ortiz AD, Jiménez-Rodríguez BM, López-Ramírez C, et al. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain. BMJ Open Respir Res. 2024;11(1):e001687. doi: 10.1136/bmjresp-2023-001687
- Richeldi L, Azuma A, Cottin V, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF). BMJ Open Resp Res. 2023;10(1):e001563. doi: 10.1136/bmjresp-2022-001563
- Lancaster L, Cottin V, Ramaswamy M, et al. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Study. Am J Respir Crit Care Med. 2024;210(4):424-34. doi: 10.1164/rccm.202403-0636OC
- ERS Congress 2024 – Annual Congress of the European Respiratory Society. Vienna, 2024.
- Corte TJ, Behr J, Cottin V, et al. Efficacy and safety of Admilparant, an LPA1 antagonist in pulmonary fibrosis. Am J Respir Crit Care Med. 2025;211(2):230-8. doi: 10.1164/rccm.202405-0977OC
- Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON-PPF Phase 3, randomized, controlled clinical trial of inhaled treprostinil in the treatment of progressive pulmonary fibrosis. CHEST Pulmonary. 2024;3(2):100124. doi: 10.1016/j.chpulm.2024.100124
- Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325-34. doi: 10.1056/NEJMoa2008470
- Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2022;9(1):e001310. doi: 10.1136/bmjresp-2022-001310
- Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH). Lancet Respir Med. 2024;12(4):273-80. doi: 10.1016/S2213-2600(23)00432-0
- Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18-47. doi: 10.1164/rccm.202202-0399ST
- Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: An expert group consensus statement. Eur Respir J. 2023;61(3):2103187. doi: 10.1183/13993003.03187-2021
- Shigeki M. Progressive fibrosing interstitial lung diseases: A new concept and indication of Nintedanib. Mod Rheumatol. 2020;31(1):13-9. doi: 10.1080/14397595.2020.1826665
- Kuwana M, Azuma A. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol. 2020;30(2):225-31. doi: 10.1080/14397595.2019.1696505
- Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-86. doi: 10.1016/S2213-2600(20)30554-3
- Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0
- Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-86. doi: 10.1016/S2213-2600(20)30554-3
- Руководство по экспертизе лекарственных средств. М.: Гриф и К, 2014. Т. I [Rukovodstvo po ekspertize lekarstvennykh sredstv. Moscow: Grif i K, 2014. T. I (in Russian)].
Supplementary files
